Peptide dosing
With peptides and GLP-1 medications, dose is most of the story: how much, how often, how to step up without inviting side effects, and how to reconstitute a vial correctly. These articles collect what we've written on peptide dosing — titration schedules, injection frequency, microdosing debates, and technique.
One thing you won't find is a personal protocol: that's your prescriber's job. Every Promise treatment comes with provider oversight, and dosing decisions belong in that conversation. Where a compound has its own dosing article, you'll find the specifics there.
62 articles on this topic
-
MOTS-c Half-Life: What Is Actually Known
No published study has measured how long the body takes to clear a dose of MOTS-c. Here is what the rodent work, the exercise data and one unpublished Phase 1 trial actually show.
-
Tesamorelin Half-Life Is Measured in Minutes
Tesamorelin leaves the bloodstream quickly, but the signal it starts can last much longer. That difference explains why trials used it once daily and why providers follow IGF-1 instead of watching the clock.
-
Kisspeptin for Men: What the Studies Really Show
Kisspeptin may affect reproductive hormones and sexual response in men. The evidence is promising but small, and it does not establish a standard dose or long-term treatment plan.
-
Tesamorelin Injections: Sites, Timing, and Storage
Tesamorelin is injected under the skin once daily. The abdomen, site rotation, timing, device format, and storage instructions all matter—and they are not identical across branded and compounded formulations.
-
BPC-157 Half-Life: What the Evidence Shows
The human half-life of BPC-157 has not been established. Animal studies measured the intact peptide in minutes, not hours, while detection tests and biological effects answer different questions.
-
Semaglutide Injections: A Practical Guide
Semaglutide is usually injected once a week, but the device, missed-dose rule, storage window and disposal steps depend on the exact product prescribed.
-
Sermorelin Injections: Sites and Expectations
Sermorelin is injected into the fatty layer beneath the skin, commonly around bedtime. The dose, schedule, site plan, and storage instructions come from the prescriber and dispensing pharmacy—not a universal online protocol.
-
Tirzepatide Injections: A Practical Guide
Tirzepatide injections deliver prescribed tirzepatide under the skin once weekly. The device may be a prefilled pen, a four-dose KwikPen, or a vial used with a syringe, and each format has its own instructions.
-
GHK-Cu Dosage: How Prescribers Set the Amount
There is no validated human injection dose for GHK-Cu. Topical studies disclose several concentrations, while compounded injection amounts come from clinical practice and must be tied to the exact vial and the person being treated.
-
Semaglutide Before Surgery: Do You Need to Stop?
Most patients can continue semaglutide before an elective procedure, but the plan changes when delayed stomach emptying is more likely. The anesthesia and prescribing teams should make that call together.
-
Tirzepatide Plateau: Why Weight Loss Slows
A tirzepatide plateau is usually the point where a smaller body and stronger biological pressure to maintain weight balance the medication's effects. A brief stall is not the same thing, and a prescriber should review the pattern before changing treatment.
-
NAD Injection Dosage: What Human Studies Used
There is no validated subcutaneous or intramuscular NAD+ schedule. The best-known IV pharmacokinetic study used 750 mg over six hours, so a prescriber must set route, concentration, amount and frequency together.
-
Tirzepatide and Birth Control: The 4-Week Rule
Tirzepatide may reduce the absorption of birth control taken by mouth. The current U.S. labels advise non-oral contraception or an added barrier method for four weeks after starting and after every dose increase.
-
Tirzepatide Constipation: How Long It Lasts
Tirzepatide constipation is common, especially in the first weeks and after dose increases. It often eases as treatment stabilizes, while severe or persistent symptoms need a clinician’s attention.
-
What Happens When You Stop Taking Tirzepatide?
Appetite suppression fades as tirzepatide clears, and weight regain is common but neither immediate nor inevitable. SURMOUNT-4 shows the difference between stopping and continuing over one year.
-
Epitalon Dosage: How a Prescriber Decides
Published evidence does not establish a standard dose. One small human AEDG study used 0.5 mg daily under the tongue for 20 days; injection-cycle numbers often come from animal work or studies of a different pineal extract.
-
How Often Do You Inject Peptides?
Injection frequency can range from nightly to once weekly because each peptide has a different half-life, mechanism, and formulation. The prescription label for the exact vial sets the schedule.
-
GLP-1 Drops: What the Absorption Evidence Shows
GLP-1 drops promise a needle-free shortcut, but the delivery system is the whole question. No published human clinical evidence yet shows that sublingual semaglutide drops achieve meaningful absorption or weight-loss efficacy.
-
SS-31 Peptide Dosage: What the Trials Used
Human elamipretide studies have used multiple regimens, including weight-based intravenous infusions and, in PROGRESS-HF, 4 mg or 40 mg subcutaneously once daily; several later disease trials used 40 mg daily. Those figures are trial parameters rather than a protocol anyone can lift — outside a trial there is no established dose.
-
How Long Does Tirzepatide Stay in Your System?
Tirzepatide usually takes about 25–30 days to fall to a small fraction of its starting level after the last dose. Its five-to-six-day half-life explains that estimate, but side effects and clinical effects do not end on one exact day.
Page 2 of 4 · 62 articles